

MYM NUTRACEUTICALS INC.

**CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE MONTHS ENDED FEBRUARY 28, 2018**

(Expressed in Canadian Dollars)

(Unaudited)

**NOTICE OF NO AUDITOR REVIEW OF CONDENSED INTERIM CONSOLIDATED FINANCIAL
STATEMENTS**

Under National Instrument 51-102, Part 4, subsection 4.3 (3) (a), if an auditor has not performed a review of the consolidated interim financial statements, they must be accompanied by a notice indicating that an auditor has not reviewed the financial statements.

The accompanying unaudited condensed interim consolidated financial statements of the Company have been prepared by and are the responsibility of the Company's management.

The Company's independent auditor has not performed a review of these financial statements in accordance with standards established by the Canadian Institute of Chartered Accountants for a review of the consolidated interim financial statements by an entity's auditor.

MYM NUTRACEUTICALS INC.
CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
(Expressed in Canadian Dollars)
(Unaudited)

	FEBRUARY 28 2017	MAY 31 2017
ASSETS		
Current Assets		
Cash and cash equivalents (Note 11)	\$ 10,105,718	\$ 548,514
Amounts receivable (Note 3)	760,187	40,517
Deposits and prepaid expenses	656,461	208,601
Due from related parties (Note 10)	390,487	-
Inventory (Note 4)	100,197	37,906
Total Current Assets	12,013,050	835,538
Non-current Assets		
Advances on acquisitions (Note 5)	610,387	-
Goodwill (Note 10)	888,056	888,056
Intangible assets (Note 7)	2,668,514	8,991
Property, plant, and equipment (Note 6)	4,270,523	35,781
TOTAL ASSETS	\$ 20,450,530	\$ 1,768,366
LIABILITIES		
Current Liabilities		
Accounts payable and accrued liabilities	\$ 808,822	\$ 255,659
Deferred sales	72,751	-
Due to related parties (Note 10)	205,819	1,004
Total Current Liabilities	1,087,392	256,663
Royalty provision on acquisition (Note 11)	195,000	-
Total Liabilities	1,282,392	256,663
EQUITY		
Share capital (Note 9)	19,119,752	3,051,623
Share subscriptions received	-	843,582
Reserves	6,261,707	199,096
Contingent consideration (Note 8 & 14)	115,000	345,000
Deficit	(6,024,714)	(2,879,966)
Equity attributable to shareholders of the Company	19,471,745	1,559,335
Non-controlling interest	(303,607)	(47,632)
Total Equity	19,168,138	1,511,703
TOTAL LIABILITIES AND EQUITY	\$ 20,450,530	\$ 1,768,366

Nature of operations and going concern (Note 1)
Commitments and contingencies (Note 14)
Events after the reporting period (Note 15)

These consolidated financial statements were approved and authorized for issue for the Board of Directors on April 26, 2018. They are signed on the Company's behalf by:

“Erick Factor”
Director

“Rob Gietl”
Director

The accompanying notes are an integral part of these consolidated financial statements.

MYM NUTRACEUTICALS INC.
CONDENSED INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS AND
COMPREHENSIVE LOSS
(Expressed in Canadian Dollars)
(Unaudited)

	THREE MONTHS ENDED FEBRUARY 28		NINE MONTHS ENDED FEBRUARY 28	
	2018	2017	2018	2017
Revenues	\$ 477,580	\$ -	\$ 1,156,109	\$ -
Cost of Sales	(81,754)	-	(324,112)	-
Gross Profit	395,826	-	831,997	-
General and administrative expenses				
Advertising, marketing and promotions	\$ 576,908	\$ 5,750	\$ 1,010,084	\$ 7,985
Amortization and depreciation	13,294	-	14,205	-
Bad debt expense (recovery)	(2,500)	-	(2,500)	-
Consulting fees	216,038	54,062	407,798	75,562
Corporate filing and listing fees	26,048	5,225	42,167	14,955
Foreign exchange	176	673	785	673
Insurance	8,551	-	19,434	-
Interest and bank charges	2,443	194	3,848	349
Interest on notes payable (Note 10)	-	947	-	6,211
Meals and entertainment	17,191	2,257	41,057	2,544
Office and miscellaneous	36,437	1,758	110,660	2,843
Professional fees	9,845	(2,026)	111,989	3,323
Rent	104,296	-	176,984	-
Salaries and management fees (Note 10)	675,157	22,000	1,104,655	52,000
Shipping costs	41,574	-	76,529	-
Stock based compensation (Note 9)	369,806	6,706	943,545	12,889
Training and education	-	-	14,900	-
Travel	76,296	2,628	129,100	4,944
Utilities	23,931	-	27,480	-
	2,195,491	100,174	4,232,720	184,278
Net Loss from Operations	(1,799,665)	(100,174)	(3,400,723)	(184,278)
Writedown of deposit	-	-	-	(15,000)
Net Loss And Comprehensive Loss	\$ (1,799,665)	\$ (100,174)	\$ (3,400,723)	\$ (199,278)
Net loss attributable to:				
MYM Nutraceuticals Inc.	(1,678,847)	(100,174)	\$ (3,144,748)	(199,278)
Non-controlling interest	(120,818)	-	(255,975)	-
	(1,799,665)	(100,174)	\$ (3,400,723)	(199,278)
Basic And Diluted Loss Per Common Share	\$ (0.02)	\$ (0.00)	\$ (0.04)	\$ (0.00)
Weighted Average Number Of Common Shares Outstanding	98,160,901	54,987,423	91,098,862	54,287,528

The accompanying notes are an integral part of these consolidated financial statements.

MYM NUTRACEUTICALS INC.
CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS
(Expressed in Canadian Dollars)

	NINE MONTHS ENDED	
	FEBRUARY 28	
	2018	2017
Cash Flows Provided By (Used In):		
Operating Activities		
Net loss for the period	\$ (3,400,723)	\$ (199,278)
Items not affecting cash		
Amortization and depreciation	14,205	-
Share-based payments	943,545	12,889
Net change in non-cash working capital items:		
Accounts receivable	(646,919)	(3,183)
Deposits and prepaids	(447,860)	(90,806)
Inventory	(62,291)	-
Accounts payable and accrued liabilities	545,663	(28,894)
Due from related parties	(185,672)	62,814
Interest Payable	-	2,123
	(3,240,052)	(244,335)
Financing Activities		
Proceeds from private placements	15,198,768	431,125
Proceeds from exercise of warrants	2,206,898	46,750
Proceeds from exercise of options	321,500	-
Share subscriptions	-	(18,025)
Share issue costs	(157,616)	-
Cash used to pay back loans		(45,000)
	17,569,550	414,850
Investing Activities		
Acquisition of assets	(400,498)	-
Acquisition of intangible assets	(236,710)	-
Advances on acquisitions	(286,637)	-
Construction in progress	(3,848,449)	-
	(4,772,294)	-
Net Increase (Decrease) In Cash	9,557,204	170,515
Cash, Beginning Of The Period	548,514	145,156
Cash, End Of The Period	\$ 10,105,718	\$ 315,671

Supplemental cash flow information (Note 13)

The accompanying notes are an integral part of these consolidated financial statement

MYM NUTRACEUTICALS INC.
CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (DEFICIENCY)
FOR THE NINE MONTHS ENDED FEBRUARY 28, 2018

(Expressed in Canadian Dollars)

(Unaudited)

	<u>SHARE CAPITAL</u>		<u>SHARES TO BE ISSUED AND SUBSCRIPTIONS RECEIVED</u>	<u>RESERVE FOR WARRANTS</u>	<u>RESERVE FOR OPTIONS</u>	<u>CONTINGENT CONSIDERATION</u>	<u>DEFICIT</u>	<u>NON-CONTROLLING INTEREST</u>	<u>TOTAL EQUITY</u>
Balance, May 31, 2016	53,300,001	\$ 1,644,748	\$ 25,525	\$ 38,715	\$ 125,332	\$ -	(2,033,281)	-	(198,961)
Shares issued	8,846,428	431,125	(25,525)	-	-	-	-	-	405,600
Shares issued for exercise of warrants	935,000	46,750	-	-	-	-	-	-	46,750
Shares issued for business acquisition	1,000,000	65,000	-	-	-	-	-	-	65,000
Share subscriptions received	-	-	7,500	-	-	-	-	-	7,500
Stock based compensation	-	-	-	-	12,889	-	-	-	12,889
Net loss for the period	-	-	-	-	-	-	(199,278)	-	(199,278)
Balance, February 28, 2017	64,081,429	\$ 2,187,623	\$ 7,500	\$ 38,715	\$ 138,221	\$ -	\$ (2,232,559)	\$ -	\$ (139,500)
Shares issued for exercise of warrants	100,000	5,000	-	-	-	-	-	-	5,000
Shares issued for business acquisition	3,300,000	759,000	-	-	-	-	-	-	759,000
Share subscriptions received	-	-	836,082	-	-	-	-	-	836,082
Stock based compensation	500,000	100,000	-	-	22,160	-	-	-	122,160
Contingent consideration	-	-	-	-	-	345,000	-	-	345,000
Net loss for the period	-	-	-	-	-	-	(647,407)	(47,632)	(695,039)
Balance, May 31, 2017	67,981,429	\$ 3,051,623	\$ 843,582	\$ 38,715	\$ 160,381	\$ 345,000	\$ (2,879,966)	\$ (47,632)	\$ 1,511,703
Shares and warrants issued on private placements	17,757,439	10,093,481	(836,082)	5,941,369	-	-	-	-	15,198,768
Shares issued for exercise of warrants	14,506,871	2,206,898	-	-	-	-	-	-	2,206,898
Shares issued for exercise of options	3,187,500	321,500	-	-	-	-	-	-	321,500
Shares issued for business acquisitions ⁽¹⁾	2,937,500	2,781,563	-	-	-	(230,000)	-	-	2,551,563
Share issue costs	-	(157,616)	-	-	-	-	-	-	(157,616)
Share subscriptions refunded	-	-	(7,500)	-	-	-	-	-	(7,500)
Fair value options exercised	-	154,753	-	-	(154,753)	-	-	-	-
Fair value of warrants exercised	-	123,051	-	(123,051)	-	-	-	-	-
Stock based compensation	932,062	544,499	-	27,612	371,434	-	-	-	943,545
Net loss for the period	-	-	-	-	-	-	(3,144,748)	(255,975)	(3,400,723)
Balance, February 28, 2018	107,302,801	19,119,752	\$ -	\$ 5,884,645	\$ 377,062	\$ 115,000	\$ (6,024,714)	\$ (303,607)	\$ 19,168,138

(1) A summary of shares issued for business acquisitions

	Shares	Share Capital
CannaCanada Inc. acquisition	437,500	\$ 202,188
CannaCanada Inc. finder's fee	25,000	8,625
Mary Jane's Touch acquisition	500,000	153,000
Hempmed acquisition contingent shares	1,000,000	230,000
Budly acquisition	800,000	1,864,000
Solaris Nutraceuticals Inc. finder's fee	175,000	323,750
Shares issued for business acquisitions	2,937,500	\$ 2,781,563

The accompanying notes are an integral part of these consolidated financial statements.

MYM NUTRACEUTICALS INC.
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE MONTHS ENDED FEBRUARY 28, 2018
(Expressed in Canadian Dollars)
(Unaudited)

1. NATURE OF OPERATIONS AND GOING CONCERN

MYM Nutraceuticals Inc. (the “Company” or “MYM”) was incorporated pursuant to the Business Corporations Act of British Columbia (“BCABC”) on July 11, 2014, under incorporation number BC1002050. The address of the Company’s corporate office and principal place of business is Suite 1500 - 409 Granville Street, Vancouver, British Columbia, Canada. The Company was a wholly owned subsidiary of Salient Corporate Services Inc. and was created for the purpose of giving effect to an Arrangement Agreement among MYM, Salient Corporate Services Inc. (“Salient”), and Adera Minerals Corp. (“Adera”). Adera was incorporated on February 18, 2011 under the Business Corporations Act of British Columbia. During the year ended May 31, 2017, Adera Minerals Corp. was renamed to Joshua Tree Brands Inc.

The Company is in the business of acquiring and developing natural remedies and currently holds the rights to various intangible assets including intellectual property, domain names and copyrights, customer lists, and has two active applications to become a licensed producer under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”) in Quebec, Canada.

Although the Company continues to invest resources for a medical marijuana business, there is no guarantee the Company will be awarded a license to grow medical marijuana nor is there a time frame available as to when the Company will be notified of the success of its application.

As at February 28, 2018, the Company has an accumulated deficit of \$6,024,714 (May 31, 2017 - \$2,879,966). The Company’s operations are mainly funded with equity financing, which is dependent upon many external factors and may be difficult to raise when required. The Company may not have sufficient cash to fund the acquisition and development to commercial production and therefore will require additional funding, which if not raised, may result in the delay, postponement or curtailment of some of its activities. Management continues to evaluate the need for additional financing and is of the opinion that additional financing will be available to continue its planned activities in the normal course. Nonetheless, there is no assurance that the Company will be able to raise sufficient funds in the future to complete its planned activities. All of which indicate the existence of a material uncertainty that may cast substantial doubt on whether the Company would continue as a going concern and realize its assets and settle its liability and commitments in the normal course of business.

The Company’s condensed interim consolidated financial statements (“interim financial statements”) have been prepared on the basis of accounting principles applicable to a going concern, which assume the realization of assets and discharge of liabilities in the normal course of business. These interim financial statements do not give effect to any adjustments that would be necessary should the Company not be able to continue as a going concern. Such adjustments could be material.

MYM NUTRACEUTICALS INC.
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE MONTHS ENDED FEBRUARY 28, 2018
(Expressed in Canadian Dollars)
(Unaudited)

2. BASIS OF PRESENTATION

a) Statement of Compliance

These interim financial statements, including comparatives, have been prepared in accordance with International Accounting Standard ("IAS") 34, *Interim Financial Reporting* using accounting policies consistent with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") and interpretations of the International Financial Reporting Interpretations Committee ("IFRIC"). Accordingly, these interim financial statements do not include all of the information and footnotes required by IFRS for complete financial statements for year-end reporting process.

b) Basis of Measurement

These interim financial statements have been prepared on a historical cost basis except for certain financial instruments that have been measured at fair value. In addition, these interim financial statements have been prepared using the accrual basis of accounting, except for cash flow information.

c) Functional and Presentation Currency

The presentation and the functional currency of the Company and its subsidiaries is the Canadian dollar.

Transactions in currencies other than the functional currency are recorded at the rates of exchange prevailing on the dates of the transactions. At each financial position reporting date, monetary assets and liabilities that are denominated in foreign currencies are translated at the rates prevailing at the date of the statement of financial position. Non-monetary items that are measured in terms of historical cost in a foreign currency are not retranslated.

d) Significant Accounting Judgments and Estimates

The preparation of these interim financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual outcomes could differ from these estimates. The interim financial statements include estimates which, by their nature, are uncertain. The impacts of such estimates are pervasive throughout the consolidated financial statements, and may require accounting adjustments based on future occurrences. Revisions to accounting estimates are recognized in the period in which the estimate is revised and may affect both the period of revision and future periods.

MYM NUTRACEUTICALS INC.
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE MONTHS ENDED FEBRUARY 28, 2018
(Expressed in Canadian Dollars)
(Unaudited)

2. BASIS OF PRESENTATION (continued)

d) Significant Accounting Judgments and Estimates (continued)

Significant assumptions about the future and other sources of estimation uncertainty that management has made at the statement of financial position date, that could result in a material adjustment to the carrying amounts of assets and liabilities, in the event that actual results differ from assumptions made, relate to, but are not limited to, the following:

Judgements:

- The carrying value and recoverable amount of intangible assets;
- the assumption that the Company is a going concern and will continue in operation for the foreseeable future and at least one year.
- The Company assesses the collectability of receivables on an ongoing basis. A provision for the impairment of receivables involves significant management judgment and includes the review of individual receivables based on individual customer creditworthiness, current economic trends and analysis of historical bad debts.
- The Company assesses whether the acquisitions should be accounted and disclosed as an acquisition of assets or acquisition of a business and involves significant judgement by management of the Company.

Estimates:

- The estimated useful lives of equipment which is included in the statements of financial position and the related depreciation included in net income/loss for the period;
- the inputs used in accounting for warrants issued;
- the inputs used in accounting for share-based compensation expense in net income/loss;
- the inputs used in accounting for acquisitions acquired thru shares and options issued;
- the inputs used in assessing the recoverability of deferred income tax assets to the extent that the deductible temporary differences will reverse in the foreseeable future and that the Company will have future taxable income.

e) Operating Segments

The Company currently operates in one operating segment, therefore the operating segments of the Company are treated as one reporting segment

f) Basis of Consolidation

These interim financial statements include the accounts of the Company and all of its subsidiaries: CannaCanada Inc., Joshua Tree Brands Inc., My Marijuana Natural Products Inc, MYM Holdings Inc., MYM Holdings (WA) Inc. (incorporated in the State of Washington), Sublime Culture Inc., and 1114865 B.C. Ltd.

All subsidiaries are entities that we control, either directly or indirectly. Control is defined as the exposure, or rights, to variable returns from involvement with an investee and the ability to affect those returns through power over the investee. Power over an investee exists when our existing rights give us the ability to direct the activities that significantly affect the investee's returns. This control is generally evidenced through owning more than 50% of the voting rights or currently exercisable potential voting rights of a company's share capital.

MYM NUTRACEUTICALS INC.
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE MONTHS ENDED FEBRUARY 28, 2018
(Expressed in Canadian Dollars)
(Unaudited)

2. BASIS OF PRESENTATION (continued)

f) Basis of Consolidation (continued)

All of our intra-group balances and transactions, including unrealized profits and losses arising from intra-group transactions, have been eliminated in full. For subsidiaries that we control but do not own 100% of, the net assets and net profit attributable to outside shareholders are presented as amounts attributable to non-controlling interests in the consolidated statements of financial position and consolidated statements of operations and comprehensive loss.

3. AMOUNTS RECEIVABLE

	February 28, 2018	May 31, 2017
Trade receivables	\$ 42,321	\$ 10,038
GST/HST/QST receivables	705,764	27,466
Other receivables	13,539	6,950
Allowance for doubtful accounts	(1,437)	(3,937)
	\$ 760,187	\$ 40,517

An allowance for doubtful accounts of \$1,447 (May 31, 2017: \$3,937) has been provided against these receivable amounts, which the Company has determined represents a reasonable estimate of amounts that may be uncollectible.

4. INVENTORY

	February 28, 2018	May 31, 2017
Raw materials and packaging	\$ 22,196	\$ 9,000
Work in progress	34,802	-
Finished product	35,811	28,906
Marketing materials	7,388	-
	\$ 100,197	\$ 37,906

5. ADVANCES ON ACQUISITIONS

On October 18, 2017, MYM announced a partnership with PUF Ventures Inc. (PUF) for the construction of a one million square foot facility called the Northern Rivers Project in New South Wales, Australia. The North Rivers Project is a partnership with the local government in New South Wales, Australia. MYM will own 35% of the Project, which will have the ability to produce at capacity 100,000 kilograms of cannabis.

PUF has entered into an agreement in principal whereby it will receive a 70% interest comprising 70 shares in Solaris Nutraceuticals Pty Ltd. (formerly "PUF Ventures Australia") if certain funding obligations totalling USD\$1 million are made (the "Obligations"). PUF and MYM have entered into a Share Purchase Agreement whereby MYM will fund half of the Obligations, totalling USD\$500,000 in exchange for half of the shares (a 35% interest).

In connection with the agreement, the Company paid a finders fees of 175,000 shares valued at \$323,750 and has included the amount in advances on acquisitions

MYM NUTRACEUTICALS INC.
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE MONTHS ENDED FEBRUARY 28, 2018
(Expressed in Canadian Dollars)
(Unaudited)

5. ADVANCES ON ACQUISITIONS (Continued)

The Company is obligated under the agreement to fund 50 percent of the following milestones

1. Formation and Incorporation of Company	Investment \$50,000 USD
2. Agreement with Council/Municipality on land	Investment \$150,000 USD
3. Filing of applications to the Office of Drug Control for Cultivation	Investment \$250,000 USD
4. Awarding of license from ODC	Investment \$550,000 USD

During the nine months ended February 28, 2018, the Company advanced USD\$225,000 (CAD\$286,637) to Solaris Nutraceuticals Inc to meet its share of the obligations for the first three milestones.

6. PROPERTY, PLANT, AND EQUIPMENT

	Computers	Equipment	Construction in Progress	Total
Cost	\$	\$	\$	\$
Balance at May 31, 2016	-	-	-	-
Additions	900	-	34,915	35,815
Balance at May 31, 2017	900	-	34,915	35,815
Additions	41,791	358,707	3,848,449	4,248,947
Balance at February 28, 2018	42,691	358,707	3,883,364	4,284,762
Accumulated depreciation				
Balance at May 31, 2016	-	-	-	-
Depreciation for the year	34	-	-	34
Balance at May 31, 2017	34	-	-	34
Depreciation for the year	3,782	10,423	-	14,205
Balance at February 28, 2018	3,816	10,423	-	14,239
Net carrying amounts				
As at May 31, 2017	866	-	34,915	35,781
As at February 28, 2018	38,875	348,284	3,883,364	4,270,523

MYM NUTRACEUTICALS INC.
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE MONTHS ENDED FEBRUARY 28, 2018
(Expressed in Canadian Dollars)
(Unaudited)

7. INTANGIBLE ASSETS

	ACMPR License Applications	Intellectual Property	Domain Names	Other	Total
Cost	\$	\$	\$	\$	\$
Balance at May 31, 2016	-	-	3,350	1,500	4,850
Acquisitions	-	-	5,080	561	5,641
Impairment	-	-	-	(1,500)	(1,500)
Balance at May 31, 2017	-	-	8,430	561	8,991
Acquisitions	425,478	2,232,148	-	1,897	2,226,514
Balance at February 28, 2018	425,748	2,232,148	8,430	2,458	2,668,514

For the nine months ended February 28, 2018, there are no indicators of impairment to intangible assets. During the year ended May 31, 2017, the Company recognized an impairment loss on documentation of \$1,500.

During the nine months ended February 28, 2018, the Company entered into an asset purchase agreement to secure the exclusive rights to apply for an ACMPR license application with the City of Weedon (Note 8). The costs incurred to complete the licence application and the costs of obtaining the exclusive rights have been capitalized as an intangible asset. The Company also capitalized certain costs for the Laval ACMPR licence application.

During the three months ended February 28, 2018, the Company entered into a binding letter of intent with Budly Software Inc. ("Budly"), a leading software company that has developed a smartphone-enabled sales and distribution system and such costs have been capitalized as intellectual property.

MYM NUTRACEUTICALS INC.
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE MONTHS ENDED FEBRUARY 28, 2018
(Expressed in Canadian Dollars)
(Unaudited)

8. ASSET ACQUISITIONS

CANNACANADA INC.

On June 8, 2017 (the "Closing Date") the Company acquired 75% of the outstanding common shares of CannaCanada Inc. ("CannaCanada"), a Montréal, Quebec based cannabis company. The initial consideration exchanged by the Company was cash consideration of \$105,000 cash and 187,500 common shares of the Company upon the closing of the agreement and further 250,000 shares subsequent to the Closing Date.

The Company will exchange the following additional consideration should the related milestones be achieved to trigger the issuance:

1. If the ACMPR License Application reaches the pre-license inspection stage, MYM will issue 500,000 common shares of MYM to CannaCanada.
2. If the ACMPR License Application is approved by Health Canada and the License is granted, MYM will issue 1,000,000 common shares of MYM to CannaCanada. When enacted MYM's ownership share will increase from 75% to 85%.
3. One year following the receipt of the license, MYM will issue 1,000,000 common shares of MYM to CannaCanada. When enacted MYM's ownership share will increase from 85% to 90%.
4. Once the Interpretation Centre is completed and operational, MYM will issue 1,000,000 common shares of MYM to CannaCanada.
5. Once the Hemp Facility is completed and operational, MYM will issue 1,000,000 common shares of MYM to CannaCanada.

Through the acquisition of CannaCanada, the Company entered into an exclusive deal with the Municipality of Weedon, Quebec, Canada to build a 1.5 million-square-foot cannabis facility consisting of fifteen 100,000-square-foot greenhouses. The acquisition has been accounted for by the Company as a purchase of assets and assumption of liabilities. The acquisition did not qualify as a business combination under *IFRS 3 - Business Combinations*, as the significant inputs, processes and outputs, that together constitute a business, do not currently exist in CannaCanada. The primary asset of CannaCanada is the value of the ACMPR License Application with the Municipality of Weedon and Health Canada.

Due to an administrative delay in issuing the initial shares, the Company amended the timing of the issuance of the 187,500 shares to June 20, 2017. The fair value of these shares was determined using MYM's closing share price from June 19, 2017 of \$0.345 for a total of \$64,688.

The total consideration was allocated to the assets acquired and liabilities based on their relative fair values on the Closing Date as follows:

Purchase price		
Cash consideration	\$	105,000
Fair value of common shares issued, net of share issuance costs of \$nil		64,688
Transactions costs		-
	\$	169,688
Purchase price allocation		
ACMPR license application	\$	169,688

The 250,000 subsequent shares were valued at \$0.55 per share for a total of \$137,500 on issue date and capitalized in the ACMPR license application costs.

MYM NUTRACEUTICALS INC.
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE MONTHS ENDED FEBRUARY 28, 2018
(Expressed in Canadian Dollars)
(Unaudited)

8. ASSET ACQUISITIONS (Continued)

SUBLIME CULTURE INC.

On February 22, 2017, the Company acquired 51% interest in Sublime Culture Inc. (“Sublime”) and its inspection-stage application in Quebec to become a licensed producer of medical cannabis pursuant to the investment agreement dated January 27, 2017. The Company issued 1,000,000 common shares at a price of \$0.065 per share for a value of \$65,000. The Company is committed to the completion of the facility and is required to issue 200,000 options per year once the facility is operational.

The acquisition has been accounted for by the Company as a purchase of assets and assumption of liabilities. The acquisition did not qualify as a business combination under *IFRS 3 - Business Combinations*, as the significant inputs, processes and outputs, that together constitute a business, do not currently exist in Sublime.

HEMPMED

On April 11, 2017, the Company acquired 100% of the brand and assets of HempMed (“HempMed”), a Toronto-based developer and marketer of hemp-based CBD extracts and oil-infused nutraceutical products. Pursuant to the Acquisition Agreement between MYM and HempMed, the Company issued 2,500,000 common shares of the Company to the owner of HempMed, with a further 1,500,000 common shares to be issued upon reaching certain monthly and annual sales targets.

The acquisition of “HempMed” by the Company is considered to be business combination. Pursuant to the business combination transactions, the asset acquired from the acquisition is to be recorded at their estimated fair values in accordance with *IFRS 3 – Business Combination*. The allocation of the purchase consideration is as follows:

Purchase consideration	
Fair value of shares	\$ 575,000
Fair value of contingent consideration	<u>345,000</u>
Total purchase price	<u>\$ 920,000</u>
Allocation of purchase price:	
Inventory	31,944
Goodwill	<u>888,056</u>
	<u>\$ 920,000</u>

The fair value of the Company’s net assets is estimated to be consistent with their carrying value. The goodwill recognized in connection with the acquisition is primarily attributable to the application of the Company’s best practices to improve the operations of the companies acquired.

The estimated fair value of the contingent consideration liability recognized on the acquisition date is calculated using the fair value of the shares of the expected contingent consideration to be paid. During the nine months ended February 28, 2018, the Company issued 1,000,000 of the contingent common shares as operational milestones were achieved by HempMed. Accordingly, \$230,000 representing the fair value of the issued shares was reclassified to share capital from the contingent consideration equity component.

Reconciliation of Contingent Consideration	
Balance, May 31, 2017	\$ 345,000
Value attributable to contingent shares issued	<u>(230,000)</u>
Balance, February 28, 2018	<u>\$ 115,000</u>

MYM NUTRACEUTICALS INC.
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE MONTHS ENDED FEBRUARY 28, 2018
(Expressed in Canadian Dollars)
(Unaudited)

8. ASSET ACQUISITIONS (Continued)

MJT MANUFACTURING

On September 6, 2017, the Company entered into an Asset Purchase and Consulting Agreement with 9609989 Canada Inc. (d.b.a. "Mary Jane's Touch" or "MJT"), which manufactures and distributes cannabidiol ("CBD") and CBD products derived primarily from hemp and possesses numerous formulations of CBD products and research on CBD and its principals. MJT has been supplying CBD to MYM's subsidiary, Joshua Tree ("JT"), for use in Joshua Tree's products. MYM acquired MJT's intellectual property and other assets to continue to develop its innovative nutraceutical products. The Company issued 500,000 common shares upon closing of this Agreement according to the following schedule and contractual restrictions: 125,000 shares will be become free-trading nine months after issuance, and 125,000 every nine months thereafter.

As the shares issued cannot be traded for an extended period, a value of \$249,848 was assigned to the 500,000 shares issued using the Black Scholes method (average volatility 68%, expected life 0.5-2 years, risk free rate 0.70-1.34%).

The Company also entered into a consulting agreement with the principals of MJT to provide consulting services for a term of five years with an option to extend for an additional five years to provide the following services: development of new methods of CBD extraction and new products; contracting and recruiting chemists, extract artists, bakers and other experts in the cannabis industry; design, construction, staffing and management of any new production facilities; obtaining a Natural Product Number (NPN).

As part of the consulting agreement. The Company issued 250,000 options to purchase shares at \$0.45 per share on September 5, 2017, to expire one year after each vesting date. The options will vest as follows:

- 25,000 to vest six months from the date of grant
- 25,000 to vest twelve months from the date of grant
- 25,000 to vest eighteen months from the date of grant
- 25,000 to vest twenty-four months from the date of grant
- 25,000 to vest thirty-two months from the date of grant
- 25,000 to vest thirty-nine months from the date of grant
- 25,000 to vest forty-two months from the date of grant
- 25,000 to vest forty-eight months from the date of grant
- 25,000 to vest fifty-four months from the date of grant
- 25,000 to vest sixty months from the date of grant

The Company has also agreed to pay a commission of 1% on the first \$500,000 of gross sales of the Products and 0.5% thereafter produced in the new production facilities. The net present value of the contingent liability for these royalty payments was valued at \$195,000 using a 6% discount rate and is recorded on the Statement of Financial Position.

BUDLY

On January 8, 2018, the Company entered into a binding letter of intent with Budly Software Inc. ("Budly"), a leading software company that has developed a smartphone-enabled sales and distribution system connecting medicinal cannabis patients with local dispensary drivers for fast delivery and monitoring of orders. Using the system, a customer can select a dispensary, place an order, and then choose a driver to deliver it. The customer can then track the order on his smartphone and knows exactly when it will arrive. Orders can be placed via the Budly app on iOS, Android and Windows phones, and via the website www.budly.com. Pursuant to the letter of intent, MYM issued 800,000 common shares valued at \$1,864,000 (2.33 per share) in exchange for all non-U.S. rights to Budly's software and intellectual property. Should federal legislation change in the States, MYM will have first right of refusal for the rights in that country. Legal costs of \$20,148 were also allocated to the purchase price.

MYM NUTRACEUTICALS INC.
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE MONTHS ENDED FEBRUARY 28, 2018
(Expressed in Canadian Dollars)
(Unaudited)

9. SHARE CAPITAL

a) Authorized

Unlimited common shares without par value.
Unlimited preferred shares (none issued).

b) Issued and Outstanding

During the nine months ended February 28, 2018 the Company issued the following shares:

- The Company announced the closing of a non-brokered private placement of 5,502,120 units for gross proceeds of \$990,382 (\$0.18 per unit). Each unit is comprised of one common share and one non-transferable share purchase warrant with each warrant exercisable into one additional common share at a price of \$0.40 for a period of one year. The securities issued are subject to a four month and one day hold period under securities law. A finders' fee of \$720 was paid on the financing. A value of \$200,290 was assigned to the warrants issued using the Black Scholes method (average volatility 70%, expected life 0.75 years, risk free rate 0.70%).
- The Company announced the closing of a non-brokered private placement of 6,480,000 units for gross proceeds of \$3,240,000 (\$0.50 per unit). Each unit is comprised of one common share and one non-transferable share purchase warrant with each warrant exercisable into one additional common share at a price of \$0.40 for a period of one year. The securities issued are subject to a four month and one day hold period under securities law. Finders' fees of \$115,033 were paid on the financing. A value of \$249,848 was assigned to the warrants issued using the Black Scholes method (average volatility 69%, expected life 0.75 years, risk free rate 1.34%).
- The Company announced the closing of a non-brokered private placement of 240,000 shares for gross proceeds of \$600,000 (\$2.50 per unit). The securities issued are subject to a four month and one day hold period under securities law. There are no warrants issued in connection with this placement and no finders' fees were paid on the financing.
- The Company announced the closing of a non-brokered private placement of 5,000,000 units for gross proceeds of \$10,000,000 (\$2.00 per unit). Each unit is comprised of one common share and one transferable share purchase warrant with each warrant exercisable into one additional common share at a price of \$3.00 for a period of two years. The securities issued are subject to a four month and one day hold period under securities law. No finders' fees were paid on the financing. A value of \$5,112,747 was assigned to the warrants issued using the Black Scholes method (average volatility 97.3%, expected life 1.5 years, risk free rate 1.82%).
- The Company announced the closing of a non-brokered private placement of 535,319 units for gross proceeds of \$1,204,468 (\$2.25 per unit). Each unit is comprised of one common share and one transferable share purchase warrant with each warrant exercisable into one additional common share at a price of \$3.25 for a period of two years. The securities issued are subject to a four month and one day hold period under securities law. No finders' fees were paid on the financing. A value of \$378,484 was assigned to the warrants issued using the Black Scholes method (average volatility 98.3%, expected life 1.5 years, risk free rate 1.79%).
- The Company issued 14,506,871 shares for the exercise of warrants at \$0.05-\$1.00 per share for gross proceeds of \$2,206,898. The fair value of the warrants exercised \$123,051 was reclassified to share capital from reserves.
- The Company issued 3,187,500 shares for the exercise of options at \$0.05-\$0.48 per share for gross proceeds of \$321,500. The fair value of the options exercised \$154,753 was reclassified to share capital from reserves.
- The Company issued 187,500 shares at an issue price of \$0.345 and 250,000 shares at an issue price of \$0.55 to complete the initial acquisition of CannaCanada Inc. A finder's fee of 25,000 shares \$0.345 per share was issued on the transaction.

MYM NUTRACEUTICALS INC.
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE MONTHS ENDED FEBRUARY 28, 2018
(Expressed in Canadian Dollars)
(Unaudited)

9. SHARE CAPITAL (Continued)

b) Issued and Outstanding (Continued)

- Pursuant to the Acquisition Agreement between MYM and NetZero Group for the acquisition of the HempMed assets the Company issued 1,000,000 shares to the owner of NetZeroGroup upon reaching the required monthly sales target of \$75,000 per month over 3 consecutive months.
- The Company announced the appointment of a new Director who will serve as Executive Chairman. Pursuant to an executive agreement, the Company issued 500,000 common shares as a signing bonus. The Company recorded \$100,000 to stock-based compensation based on \$0.20 per share on date of issue.
- The Company issued 50,000 shares of the Company to a consultant as a signing bonus and agreed to issue an additional 100,000 shares if certain conditions for receipt and approval of a cultivation licence and approval for sales and distribution by health Canada. The Company recorded \$28,000 to stock-based compensation based on \$0.28 per share on date of issue.
- Pursuant to the Acquisition Agreement between MYM and Mary Janes the Company issued 500,000 shares for the acquisition of intellectual property at a price of \$0.45 per share for a value of \$225,000.
- The Company issued 300,000 shares at an issue price of \$0.55 per share in satisfaction of a \$165,000 signing bonus for a consulting agreement with International Cannabis Consultants Co. (“**Incanco**”), leading authorities on the legal framework of cannabis legislation in Canada. The Company also agreed to pay three 50,000 share milestone bonuses on the 4, 8, and 12 month anniversary of the agreement. Incanco was also issued 150,000 common share purchase warrants (each a “Warrant”), with each Warrant entitling Incanco to acquire one common share in the capital of MYM for a period of 36 months from the Warrant’s grant date. The exercise price of each Warrant is \$0.55. A value of \$27,612 was assigned to the warrants issued using the Black Scholes method (average volatility 69%, expected life 1.5 years, risk free rate 1.34%).
- The Company issued 25,000 shares of the Company to a Quality Assurance consultant as a signing bonus at an issue price of \$2.04 for a value of \$51,000 charged to Stock based compensation.
- The Company issued 175,000 shares as a finders fee for the Solaris Nutraceuticals acquisition at \$1.85 per share for a valuation of \$323,750.
- The Company entered into a consulting agreement with a Master Breeder at the Sublime facility in Laval, Québec. Pursuant to the five-year consulting agreement, the consultant will receive a signing bonus of \$25,000, paid in 7,062 MYM common shares at a deemed price per share of \$3.54.
- The Company issued 50,000 milestone shares to a consultant.
- The Company issued 800,000 common shares valued at \$1,864,000 (2.33 per share) for the acquisition of the Budly assets.

During the year ended May 31, 2017 the Company issued the following shares:

- 746,428 units were issued at a price of \$0.035 per unit for gross proceeds of \$26,125. Each unit consists of one common share and one non-transferable share purchase warrant. Each warrant entitles the holder to acquire one additional common share exercisable until October 18, 2018 at a price of \$0.05 per warrant share. No finders’ fees are payable on this placement.
- 8,100,000 units were issued at a price of \$0.05 per unit for gross proceeds of \$405,000. Each unit consists of one common share and one non-transferable share purchase warrant. Each warrant entitles the holder to acquire one additional common share exercisable until February 9, 2019 at a price of \$0.07 per warrant share. No finders’ fees are payable on this placement.
- 1,035,000 shares were issued for the exercising of warrants at \$0.05 per share for gross proceeds of \$51,750.
- 1,000,000 shares were issued for the 51% acquisition of Sublime Culture Inc at a price or \$0.065 per share for a value of \$65,000.

MYM NUTRACEUTICALS INC.
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE MONTHS ENDED FEBRUARY 28, 2018
(Expressed in Canadian Dollars)
(Unaudited)

9. SHARE CAPITAL (continued)

b) Issued and Outstanding (continued)

- 2,500,000 shares were issued for the business acquisition of HempMed at a price of \$0.23 per share for a value of \$575,000.
- 800,000 shares were issued as a finder's fees for the HempMed acquisition at a price of \$0.23 per share for a value of \$184,000.
- 500,000 shares were issued in lieu of a Cash signing bonus for the hiring of a new CEO \$0.20 per share for a value of \$100,000. The amount is included with stock-based compensation on the statement of operations and comprehensive loss.

c) Escrow Shares

There were no shares held in escrow as at February 28, 2018 or May 31, 2017.

d) Warrants

A summary of the changes in the Company's share purchase warrants is as follows:

	Number of warrants	Weighted Average Exercise Price
Balance, May 31, 2016	4,445,000	\$ 0.07
Issued	8,846,428	\$ 0.07
Exercised	(1,035,000)	\$ 0.05
Expired	(15,000)	\$ (0.10)
Balance, May 31, 2017	12,241,428	\$ 0.07
Issued	17,667,439	\$ 1.44
Exercised	(14,506,871)	\$ 0.15
Balance, February 28, 2018	11,273,787	\$ 1.57

The share purchase warrants outstanding and exercisable at February 28, 2018 are:

Number of warrants	Exercise price	Expiry date
-	\$ 0.08	December 4, 2017
-	\$ 0.05	April 29, 2018
2,401,677	\$ 0.40	June 2, 2018
30,000	\$ 0.05	October 18, 2018
5,554,000	\$ 1.00	October 24, 2018
771,000	\$ 1.00	November 7, 2018
985,000	\$ 0.07	February 9, 2019
125,000	\$ 0.55	September 20, 2020
5,000,000	\$ 3.00	February 20, 2020
535,319	\$ 0.55	February 26, 2020
15,401,996		

e) Incentive Stock Options

The Company's Stock Option Plan ("the Plan") follows the policies of the TSX Venture Exchange regarding stock option awards granted to employees, directors and consultants. The stock option plan allows a maximum of 10% of the issued shares to be reserved for issuance under the plan.

MYM NUTRACEUTICALS INC.
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE MONTHS ENDED FEBRUARY 28, 2018
(Expressed in Canadian Dollars)
(Unaudited)

9. SHARE CAPITAL (continued)

e) Incentive Stock Options (continued)

The following grants were made during the nine months ended February 28, 2018:

- 1,000,000 options at an exercise price of \$0.23 per share. The options shall vest 12.5% quarterly with the final amount to vest at 25% over the two-year term of the agreement. The fair value of the options at grant date was \$88,318, of which \$67,238 was recorded in the nine months ended February 28, 2018 based on vesting periods.
- 500,000 options at an exercise price of \$0.48 per share. 300,000 options vest immediately and the balance will vest upon completing a financing of \$2,500,000. The fair value of the options at grant date was \$68,038, all of which was recorded in the nine months ended February 28, 2018 based on vesting periods.
- 250,000 options to purchase shares at \$0.45 per share on September 5, 2017, to expire one year after each vesting date. The options will vest as follows:
 - 25,000 to vest six months from the date of grant
 - 25,000 to vest twelve months from the date of grant
 - 25,000 to vest eighteen months from the date of grant
 - 25,000 to vest twenty-four months from the date of grant
 - 25,000 to vest thirty-two months from the date of grant
 - 25,000 to vest thirty-nine months from the date of grant
 - 25,000 to vest forty-two months from the date of grant
 - 25,000 to vest forty-eight months from the date of grant
 - 25,000 to vest fifty-four months from the date of grant
 - 25,000 to vest sixty months from the date of grant

The fair value of the options at grant date was \$44,744, of which \$10,204 was recorded in the nine months ended February 28, 2018 based on vesting periods.

- 140,000 options to a consultant to provide MYM with consulting services focused on helping MYM and its partners obtain a license for and construct a medical marijuana production facility in Richmond Valley, Australia. In lieu of consulting fees, MYM granted 140,000 options to purchase common shares in the capital of MYM, with an exercise price of \$3.37. The options shall vest in accordance with the following schedule, and expire one year after vesting:
 - 14,000 on the 3-month anniversary of the Effective Date;
 - 14,000 on the 6-month anniversary of the Effective Date;
 - 14,000 on the 9-month anniversary of the Effective Date;
 - 14,000 on the 12-month anniversary of the Effective Date;
 - 14,000 on the 15-month anniversary of the Effective Date;
 - 14,000 on the 18-month anniversary of the Effective Date;
 - 14,000 on the 21-month anniversary of the Effective Date;
 - 14,000 on the 24-month anniversary of the Effective Date;
 - 14,000 on the 27-month anniversary of the Effective Date; and
 - 14,000 on the 30-month anniversary of the Effective Date.

The fair value of the options at grant date was \$247,892, of which \$22,308 was recorded in the nine months ended February 28, 2018 based on vesting periods.

- 300,000 stock options to a director to purchase common shares with an exercise price of \$2.67. The options are exercisable for a period of 3 years at \$2.67 per share and will vest in accordance with the following schedule:
 - 75,000 on the 9-month anniversary of the Effective Date;
 - 75,000 on the 18-month anniversary of the Effective Date;
 - 75,000 on the 27-month anniversary of the Effective Date;
 - 75,000 on the 36-month anniversary of the Effective Date;

MYM NUTRACEUTICALS INC.
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE MONTHS ENDED FEBRUARY 28, 2018
(Expressed in Canadian Dollars)
(Unaudited)

9. SHARE CAPITAL (continued)

e) Incentive Stock Options (continued)

- 60,000 options to a consultant to purchase common shares with an exercise price of \$3.37. The options shall vest in accordance with the following schedule, and expire one year after vesting:
 - 15,000 on the 3-month anniversary of the Effective Date;
 - 15,000 on the 6-month anniversary of the Effective Date;
 - 15,000 on the 9-month anniversary of the Effective Date;
 - 15,000 on the 12-month anniversary of the Effective Date;

The fair value of the options at grant date was \$73,491, of which \$29,106 was recorded in the nine months ended February 28, 2018 based on vesting periods.

- 800,000 options to an officer to purchase shares at \$1.98 per share on February 26, 2018, to expire two years after each vesting date. The options will vest as follows:
 - 200,000 to vest on the one-year anniversary of the Effective Date
 - the remaining Stock Options will vest in twelve (12) equal tranches, each tranche representing 50,000 Stock Options quarterly after one (1) year anniversary of the Effective date.

The fair value of the options at grant date was \$971,326, of which \$2,980 was recorded in the nine months ended February 28, 2018 based on vesting periods.

The following grants were made during the year ended May 31, 2017:

- 250,000 options to a director with an exercise price of \$0.20. The options vest 25% after each 3-month anniversary. As at May 31, 2017 the fair value of the options at grant date was \$26,462, of which \$12,470 was recorded in the nine months ended February 28, 2018 and \$13,992 was recorded in prior year based on vesting periods.
- 2,000,000 options to the CEO with an exercise price of \$0.20. The options vest 12.5% after each three-month anniversary with the final 25% vesting after 21 months. The fair value of the options at grant date was \$146,636, of which \$95,484 was recorded in the nine months ended February 28, 2018 and \$14,874 was recorded in prior year based on vesting periods.
- 100,000 options previously granted were extended a further nine months to November 2017. No additional stock-based compensation was required in 2017 as a result of the modification of the award.

Assumptions used in the option-pricing model are as follows for the nine months ended February 28:

	2018	2017
Risk-free interest rate	0.70-1.79%	0.72%
Expected life	1-5 years	2 years
Expected volatility	68-84%	70%
Forfeiture rate	0.0%	0.0%
Dividend rate	0.0%	0.0%

MYM NUTRACEUTICALS INC.
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE MONTHS ENDED FEBRUARY 28, 2018
(Expressed in Canadian Dollars)
(Unaudited)

9. SHARE CAPITAL (continued)

e) Incentive Stock Options (continued)

A summary of the changes in the Company's stock options is as follows:

	Number of Options	Weighted Average Exercise Price
Balance, May 31, 2016	3,600,000	\$0.05
Granted	2,250,000	\$0.20
Balance, May 31, 2017	5,850,000	\$0.11
Granted	3,050,000	\$1.19
Exercised	(3,187,500)	\$0.10
Balance February 28, 2018	5,712,500	\$0.69

The following table summarizes the Company's stock options outstanding and exercisable at February 28, 2018:

NUMBER OF OPTIONS OUTSTANDING	NOTE	NUMBER OF OPTIONS EXERCISABLE	EXERCISE PRICE	EXPIRY DATE
62,500	1	62,500	0.20	February 8, 2019
2,000,000	2	750,000	0.20	April 28, 2019
900,000		900,000	0.05	November 17, 2020
1,000,000	2	250,000	0.23	June 1, 2019
200,000	3	-	0.48	August 8, 2019
250,000	4	-	0.45	Up to September 5, 2023
300,000	5	-	2.67	December 6, 2020
140,000	6	-	3.37	Up to June 18, 2021
60,000	7	-	3.37	Up to Dec 18, 2019
800,000	8	-	1.98	Up to Feb 26, 2024
5,712,500		1,962,500		

1. vested as follows: 25% after each 3-month anniversary.
2. vested as follows: 12.5% after each 3-month anniversary and 25% after 21 months.
3. balance of 200,000 options have contingent vesting on attaining a financing of \$2.5M.
4. vested as follows: 10% after each 3-month anniversary - expire 1 year after vesting date'
5. vested as follows: 25% after each 9-month anniversary
6. vested as follows: 10% after each 3-month anniversary - expire 1 year after vesting date.
7. vested as follows: 25% after each 3-month anniversary - expire 1 year after vesting date.
8. vested as follows: 200,000 after 12 months and remaining balance vesting equally over each 3-month anniversary - expire 2 years after vesting date.

MYM NUTRACEUTICALS INC.
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE MONTHS ENDED FEBRUARY 28, 2018
(Expressed in Canadian Dollars)
(Unaudited)

10. RELATED PARTY BALANCES AND TRANSACTIONS

Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the Company, directly or indirectly. Key management personnel include the Company's executive officers and Board of Director members.

The aggregate value of transactions relating to key management personnel were as follows:

	NINE MONTHS ENDED	
	FEBRUARY 28	
	2018	2017
Salaries and benefits and management fees	\$ 661,541	\$ 82,750
Stock-based compensation (vested during the period)	237,855	12,889
Total salaries and other short-term benefits	\$ 899,396	\$ 95,639

During the nine months ended February 28, the Company advanced funds to directors in the amount of \$390,487 (May 31, 2017: Nil) for travel expenses and tax deductions for options exercised.

During the nine months ended February 28, 2018, the Company advanced \$100,000 to a Company controlled by a director of a subsidiary. The funds advanced were used to pay expenditures incurred on behalf of the Company. As at February 28, 2018, there is no balance remaining in the advance account.

The Company did not enter into any new loan agreements with related parties during the nine months ended February 28, 2018. Interest expense for the nine months ended February 28, 2018 was \$nil (2017: \$6,211)

As at February 28, 2018, \$200,319 (May 31, 2017 - \$1,004) were owing to key management personnel or to a company controlled by a director or key management personnel and the amounts were included in due to related parties. The amounts payable are non-interest bearing, are unsecured, and have no specific terms of repayment.

11. MANAGEMENT OF CAPITAL

The Company's objectives when managing capital are to pursue and complete the identification and evaluation of assets, properties or businesses with a view to acquisition. The Company does not have any externally imposed capital requirements to which it is subject.

As at February 28, 2018, the Company had capital resources consisting of cash and cash equivalents. The Company manages the capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust the capital structure, the Company may attempt to issue new shares or adjust the amount of cash and cash equivalents.

The Company's investment policy is to invest excess cash in investment instruments at high credit quality financial institutions with terms to maturity selected with regards to the expected time of expenditures from continuing operations. As at February 28, 2018, the Company had 7,000,000 invested in a one year redeemable GIC at 1.35% maturing on February 26, 2019

The Company's ability to continue as a going concern is dependent upon successful completion of additional financing, continuing support of creditors and its ability to attain profitable operations.

MYM NUTRACEUTICALS INC.
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE MONTHS ENDED FEBRUARY 28, 2018
(Expressed in Canadian Dollars)
(Unaudited)

12. FINANCIAL RISK EXPOSURE AND RISK MANAGEMENT

The Company is exposed in varying degrees to a number of risks arising from financial instruments. Management's close involvement in the operations allows for the identification of risks and variances from expectations. The Company does not participate in the use of financial instruments to mitigate these risks and has no designated hedging transactions. The Board approves and monitors the risk management processes. The Board's main objectives for managing risks are to ensure liquidity, the fulfillment of obligations, the continuation of the Company's exploration activities, and limited exposure to credit and market risks. There were no changes to the objectives or the process from the prior period.

The types of risk exposure and the way in which such exposures are managed are as follows:

a) Credit Risk:

Credit risk primarily arises from the Company's cash and cash equivalents and amounts receivable. The risk exposure is limited to their carrying amounts at the statement of financial position date. Cash and cash equivalents are held as cash deposits or invested in guaranteed investment certificates with various maturity dates. The Company does not invest in asset-backed deposits or investments and does not expect any credit losses. The Company periodically assesses the quality of its investments and is satisfied with the credit rating of the bank and the investment grade of the guaranteed investment certificates. Amounts receivable primarily consists of Trade Receivables and Goods and Services Tax ("GST") credits.

b) Liquidity Risk:

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due. The Company ensures there is sufficient capital to meet short term business requirements. One of management's goals is to maintain an optimal level of liquidity through the active management of assets, liabilities and cash flows.

The Company's cash and cash equivalents are deposited in major banks or invested in guaranteed investment certificates, which are available on demand to fund the Company's operating costs and other financial demands.

c) Market Risk:

The significant market risks to which the Company is exposed are currency and interest rate risk.

d) Currency Risk:

The operating results and financial position of the Company are reported in Canadian dollars. As the Company is exploring opportunities in an international environment, some of the Company's financial instruments and transactions are denominated in currencies other than the Canadian dollar. The results of the Company's operations are subject to currency risk.

The majority of the Company's costs are incurred in Canada and are denominated in Canadian dollars. Foreign currency transactions are booked at historical cost in Canadian dollars.

MYM NUTRACEUTICALS INC.
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE MONTHS ENDED FEBRUARY 28, 2018
(Expressed in Canadian Dollars)
(Unaudited)

12. FINANCIAL RISK EXPOSURE AND RISK MANAGEMENT (Continued)

e) Interest Rate Risk:

The Company's policy is to invest excess cash in guaranteed investment certificates at fixed or floating rates of interest and cash equivalents are to be maintained in floating rates of interest in order to maintain liquidity, while achieving a satisfactory return for shareholders. As at February 28, 2018 and May 31, 2017 no cash was held in interest bearing deposits. Fluctuations in interest rates impact the value of cash and cash equivalents. The Company manages risk by monitoring changes in interest rates in comparison to prevailing market rates.

Currently, the Company believes that it is not exposed to significant interest, currency or credit risks arising from its financial instruments.

13. SUPPLEMENTAL CASH FLOW INFORMATION

	NINE MONTHS ENDED FEBRUARY 28	
	2018	2017
Non-Cash Financing And Investing Activities	\$	\$
Fair value of options exercised	(154,753)	-
Fair value of warrants issued in private placements	5,941,369	-
Fair value of warrants issued for services	27,612	-
Fair value of warrants exercised	(123,051)	-
Shares issued to acquire Sublime Culture Inc	-	65,000
Shares issued for purchase CannaCanada Inc (Note 8)	202,188	-
Shares issues for HempMed contingent consideration	230,000	-
Shares issued for finder's fees on CannaCanada	8,625	-
Shares issued for acquisition of MJT Assets	153,000	-
Shares issued for finder's fees on Solaris Nutraceuticals	323,750	-
Shares issued for Budly acquisition	1,864,000	-

14. COMMITMENTS AND CONTINGENCIES

The Company has entered into two long term lease agreements for properties to be used for Sublime Culture Inc. in Laval, Quebec.

Effective March 1, 2017 continuing to February 28, 2022, with options to extend for three additional five- year terms, the Company has committed to lease a commercial building with an area of approximately 10,000 sq. ft. The base rent is set at \$7,083 per month plus GST and QST and will be increased annually to an amount equal to the IPC Montreal region for the last year or a minimum of two percent. The base rent can be reset at each renewal period to reflect appraised market prices at that time.

Effective October 1, 2017 continuing to September 22, 2022, with options to extend for three additional five- year terms, the Company has committed to lease an additional commercial building adjacent to the first with an area of approximately 10,000 sq. ft. The base rent is set at \$7,083 per month plus GST and QST and will be increased annually by an amount equal to the IPC Montreal region for the last year or a minimum of two percent. The base rent can be reset at each renewal period to reflect appraised market prices at that time.

MYM NUTRACEUTICALS INC.
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE MONTHS ENDED FEBRUARY 28, 2018
(Expressed in Canadian Dollars)
(Unaudited)

14. COMMITMENTS AND CONTINGENCIES (Continued)

The minimum payments over the next five years are as follow:

2018	141,667
2019	170,000
2020	170,000
2021	170,000
2022	148,750
	<hr/>
	\$ 800,417
	<hr/>

The Company has entered into one long term lease agreement for properties to be used for a CBD manufacturing facility in Toronto.

Effective December 1, 2017 continuing to November 30, 2022, with options to extend for one additional five-year term, the Company has committed to lease two units in a commercial building complex with an area deemed 4,735 sq. ft. The base rent is set at \$10,259 per month plus applicable taxes and will be increased annually by \$4,735 per year. The base rent at the renewal will be negotiated and if the two parties cannot agree, shall be determined by arbitration..

The minimum payments over the next five calander years are as follow:

2018	51,296
2019	125,477
2020	130,212
2021	130,947
2022	139,682
	<hr/>
	\$ 581,514
	<hr/>

The acquisition of CannaCanada comprises a number of contingent consideration items that may be realized upon the attainment of certain milestones. If fully realized the Company has committed to issue a further 4,500,000 common shares (Note 8).

With the acquisition of Sublime, the Company is committed to provide funding for the completion and operation of the facility and upon production start-up the Company will issue Sublime 200,000 options per year (Note 9).

With the acquisition of HempMed, the Company has committed to issue a further 500,000 common shares as a contingent consideration item that may be realized upon the attainment of certain milestones (Note 10).

15. EVENTS AFTER THE REPORTING PERIOD

Pursuant to the Joint Venture Agreement for the acquisition of CannaCanada Inc. the Company issued 500,000 milestone shares.

The Company granted 140,000 options to a consultant on the Australian Project to purchase shares at \$2.41 per share on March 2, 2018, to expire one year after each vesting date. The options will vest over 27 months with 14,000 vesting immediately and 14,000 on each three month anniversary date.

MYM NUTRACEUTICALS INC.
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE MONTHS ENDED FEBRUARY 28, 2018
(Expressed in Canadian Dollars)
(Unaudited)

15. EVENTS AFTER THE REPORTING PERIOD (Continued)

The Company granted 75,000 options to an officer to purchase shares at \$2.88 per share on March 20, 2018, to expire one year after each vesting date. The options will vest as follows:

- 25,000 to vest six months from the date of grant
- 25,000 to vest twelve months from the date of grant
- 25,000 to vest eighteen months from the date of grant

The Company granted 40,000 options to an employee to purchase shares at \$2.64 per share on March 29, 2018, to expire one year after each vesting date. The options will vest as follows:

- 10,000 to vest six months from the employees start date ("April 16, 2018")
- 10,000 to vest twelve months from the employees start date
- 10,000 to vest eighteen months from the employees start date
- 10,000 to vest twenty-four months from the employees start date

The Company granted 150,000 options to an employee to purchase shares at \$2.16 per share on April 10, 2018, to expire three years after grant date. The options will vest as follows:

- 37,500 to vest six months from the date of grant
- 37,500 to vest twelve months from the date of grant
- 37,500 to vest eighteen months from the date of grant
- 37,500 to vest twenty-four months from the date of grant

The Company granted 25,000 options to an employee to purchase shares at \$2.64 per share on March 29, 2018, to expire three year after grant date. The options will vest as follows:

- 6,250 to vest six months from the employees start date ("April 3, 2018")
- 6,250 to vest twelve months from the employees start date
- 6,250 to vest eighteen months from the employees start date
- 6,250 to vest twenty-four months from the employees start date

The Company granted 20,000 options to an employee to purchase shares at \$2.64 per share on March 29, 2018, to expire three years after grant date. The options will vest as follows:

- 5,000 to vest six months from the employees start date ("April 9, 2018")
- 5,000 to vest twelve months from the employees start date
- 5,000 to vest eighteen months from the employees start date
- 5,000 to vest twenty-four months from the employees start date

The Company granted 20,000 options to an employee to purchase shares at \$2.16 per share on March 29, 2018, to expire three years after grant date. The options will vest as follows:

- 5,000 to vest six months from the employees start date ("April 9, 2018")
- 5,000 to vest twelve months from the employees start date
- 5,000 to vest eighteen months from the employees start date
- 5,000 to vest twenty-four months from the employees start date

On December 29, 2017 the Company announced that certain officers and directors of the Company would be participating in an Automatic Share Disposition Plan (ASDP). The objective of the ASDP is to facilitate the sale of common shares of MYM currently held by insiders on the open market over a period of up to two years at prevailing market prices. The ASDP will allow those MYM insiders to sell their shares in order to further diversify their respective portfolios. The Company has applied to the securities commission for approval of the plan but as at the date of this report has not yet been approved.

MYM NUTRACEUTICALS INC.
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE MONTHS ENDED FEBRUARY 28, 2018
(Expressed in Canadian Dollars)
(Unaudited)

16. EVENTS AFTER THE REPORTING PERIOD (Continued)

On January 22, 2018 the Company announced it has signed a Memorandum of Understanding (MOU) with NEWCANNA S.A.S., a leading Colombian medical cannabis company. MYM and NEWCANNA are proposing a joint venture or partnership agreement in which they would form a new, jointly owned company in Colombia. This partnership would focus on the large-scale commercial cultivation and transformation of cannabis and hemp for medical, scientific and industrial purposes and export to worldwide markets.

Subsequent to the period end, 1,086,000 warrants were exercised for proceeds of \$918,000.

Subsequent to the period end, 140,000 options were cancelled.